cancer-2018-scientifictracks

16 / 16

Page 36
Notes:
allied
academies
July 23-25, 2018 | Moscow, Russia
12th World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume: 3
Veronika Aksenova
Skolkovo Foundation, Russia
Innovative Cancer care solutions: Insights from Skolkovo Foundation
Iwill represent activities of Skolkovo Foundation that aims at
building innovative eco-system to support entrepreneurial
infrastructure, including biomedical technologies development
on the Russian market. As a Project Manager in Oncology I
will talk about success stories of start-up companies in our
portfolio that develop innovative healthcare solutions to treat
cancer. One of them is OncoTartis, Inc. (Buffalo, NY/ Moscow,
Russia) that develops a novel category of anti-cancer drugs
directed against tissue-specific targets for a subset of cancers
(breast, prostate, ovarian, melanoma and hematological
malignancies). Its leading product OT-82 is a nicotinamide
phosphoribosyltransferase (NAMPT) inhibitor being developed
to treat Acute Myeloid Leukemia (AML). Investigational New
Drug application (IND) will be submitted to FDA in the forth
quarter of 2017. Oncotartis got Skolkovo grant in 2016, became
Skolkovo Start-up Village winner in 2017 and recently got $6M
investments to support Phase 1 Clinical trials. Another success
story is represented by the example of Unim LLC, resident of
Skolkovo development zone, that designed Digital pathology©
software enabling to distantly analyze wide range of histological
slides and DICOM files, including MRT, CT scan and PET-CT in
patients with ontological diagnosis. Digital pathology© cloud
platform allows to minimize the risk of wrong diagnosis, reduce
the decision-taking time, offers a worldwide histological slides
database for research and publication purposes as well remote
expert council. The company plans to accumulate significant
amount of Medical Big Data that allows testing deep machine-
learning techniques and artificial neuronal network algorithms.
Speaker Biography
Veronika Aksenova was born in Moscow at 1990, she graduated from Cell Biology
Department at Lomonosov Moscow State University. Later she did several internships
on molecular oncology in the leading international research labs in Lausanne
University, Karolinska Insitutet in Stockholm and German Cancer Research Center
(DKFZ) in Heidelberg, Germany. Following her graduation, She started work as an
R&D engineer for” Pharmapark LLC”, Russian biotech company and participated in
the development of anti-cancer generic drugs for domestic market. Recently she got
PhD degree in Developmental Biology from Aix-Marseille University, France. Currently
she is working for an non-profit Skolkovo Foundation, Russia as a project manager
supervising start-up companies that offer innovative healthcare solutions in oncology
e: